Ms. Helen Hovenga Joins Telix as Chief People Officer
4 August 2021 – Corporate Spotlight | Telix announces the appointment of Ms. Helen Hovenga in the role of Chief People Officer.
Telix is delighted to announce that Ms. Helen Hovenga has joined the Telix executive team in the role of Chief People Officer.
Helen joins Telix from the Peter MacCallum Cancer Centre where she was Executive Director of People and Culture, overseeing 3,500 health practitioners and research employees. Helen brings over 25 years’ experience in global human resources and business, gained across large multinationals, private equity firms, and ASX listed companies. Her sector experience spans public health, finance, manufacturing, mining, automotive and retail, with household names including Afterpay, Coles, Mars, Myer, Newcrest, Toyota and VicSuper.
Helen holds a Master of Business (HR) from Charles Sturt University; a Graduate Diploma in HR Management and Industrial Relations from the Royal Melbourne Institute of Technology (RMIT) and a Bachelor of Arts, Double Major in Psychology and Politics from Swinburne University of Technology in Melbourne.
On joining Telix, Ms. Hovenga stated, “It is with great excitement that I join Telix. The Board, the Executive and the whole team are truly inspirational people. With Values of innovation, passion and collaboration, I look forward to being a part of such a purpose-driven organisation on its journey to help patients with cancer live longer, better quality lives.”
Telix CEO, Dr. Christian Behrenbruch added, “On behalf of the global team, I am delighted to welcome Helen to Telix. Her broad experience in HR, combined with deep commercial understanding, makes her the ideal candidate to help us realise our global ambitions as a high performing business built on a successful and thriving employee culture.”
We welcome Helen to the Telix team, as we work to deliver on the promise of nuclear medicine.
To view the full media release please click here.
To return to our home page please click here.
Second Industry Body Updates Guidance for Use of PSMA PET Imaging
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 21 September 2021. Telix welcomes SNMMI updated Appropriate Use Criteria for PSMA PET...
Telix at AdMeTech Summit on Precision Diagnosis and Treatment of Prostate Cancer
16 September 2021 – Clinical Spotlight | Telix to support and participate in AdMeTech 5th Global Summit on Precision Diagnosis...
NCCN Guidelines Updated to Include PSMA-PET Imaging
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 14 September 2021. Telix welcomes the updated NCCN Guidelines® for prostate cancer, which includes...
FDA Approves Phase II Kidney Cancer Therapy Study
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 14 September 2021. Telix announces the FDA has accepted the IND Application to...
Telix and Radius Sign Italian Distribution Agreement for Prostate Cancer Imaging
Melbourne (Australia) and Bologna (Italy) – 13 September 2021. Telix enters a commercial distribution agreement with Radius for Telix’s prostate...
Japanese Prostate Cancer Imaging Study Completes Enrolment
Melbourne (Australia) and Kyoto (Japan) – 9 September 2021. Telix has completed a Phase I clinical trial of TLX591-CDx for...
Telix to Collaborate with Kettering Health on Diagnostic PSMA Imaging & Targeting Theranostics
Melbourne (Australia), Indianapolis (IN, U.S.A.), and Kettering (OH, U.S.A.) – 7 September 2021. Telix announces collaboration with Kettering Health on...
Telix and Lightpoint Medical to Collaborate on Radioguided Surgery
Melbourne (Australia) – 23 August 2021. Telix announces collaboration with Lightpoint Medical to explore molecularly targeted radiation and Lightpoint SENSEI®...
Telix Half-Year Results 2021 and Company Update Conference Call
Melbourne (Australia) – 19 August 2021. Telix announces Half-Year Results 2021 and provides shareholder update
Telix Expands Prostate Cancer Activity with GenesisCare Collaboration
Melbourne (Australia) – 19 August 2021. Telix releases details of two ancillary studies under the ProstACT program, including a Phase...
Telix and Merck to Commence Pan-Cancer Clinical Combination Studies
Melbourne (Australia) – 18 August 2021. Telix announces pan-cancer clinical collaboration with Merck KGaA, Darmstadt, Germany.
Two New Studies to Explore Telix Assets in Breast Cancer Theranostics
Melbourne (Australia) – 18 August 2021. Telix announces two new studies to evaluate the potential utility of TLX591-CDx and TLX250-CDx...
Telix Progresses Novel Lung and Ovarian Cancer Theranostic APOMAB®
Melbourne and Adelaide (Australia) – 17 August 2021. Telix extends partnership with AusHealth relating to APOMAB®, a novel theranostic being...
Telix’s TLX66 in Phase II Academic Study of Pediatric Leukemia
Melbourne (Australia) and London (United Kingdom) – 17 August 2021. Telix announces Phase II academic study of TLX66 in children...
Telix H1 2021 Results and Company Update Conference Call
Melbourne (Australia) – 11 August 2021. Telix to hold investor conference call to present H1 2021 financial results and Company...
First Patient Dosed in CUPID Study of Telix’s Targeted Alpha Therapy Candidate for Prostate Cancer
Melbourne (Australia) – 5 August 2021. Telix announces the first patient has been dosed in its ‘CUPID’ Phase I study...
Ms. Helen Hovenga Joins Telix as Chief People Officer
4 August 2021 – Corporate Spotlight | Telix announces the appointment of Ms. Helen Hovenga in the role of Chief...
Telix Seneffe Production Facility: Progress Update
Melbourne (Australia) and Seneffe (Belgium) – 30 July 2021. Telix authorised to decommission first of two cyclotrons at Seneffe radiopharmaceutical...
Activities Report and Appendix 4C for June 2021 Quarter
Melbourne (Australia) – 22 July 2021. Telix provides its Appendix 4C and accompanying Activities Report for the quarter ended 30 June...
ZIRCON Phase 3 Renal Cancer Imaging Study: Progress Update
Melbourne (Australia) – 20 July 2021. Progress update on the ZIRCON Phase 3 study for the imaging of renal cancer...
Telix Appoints Gabrielle Wermenbol as Chief Financial Officer, EMEA
19 July 2021 – Corporate Spotlight | Gabrielle Wermenbol joins Telix as Chief Financial Officer, Europe, Middle East & Africa...
Kyahn Williamson Joins Telix to Lead Corporate Communications and Investor Relations
Melbourne (Australia) – 12 July 2021. Telix announces that Ms. Kyahn Williamson has joined the Telix executive leadership team in...
First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer
Melbourne (Australia) – 23 June 2021. Telix announces that a first patient has been dosed in a Phase I study...
IPAX-1 (TLX101 for Glioblastoma Therapy) Clinical Trial Update
Melbourne (Australia) – 21 June 2021. Telix announces preliminary safety data from the IPAX-1 Ph I/II study, with a follow-on...
Telix Update on FDA New Drug Application Review for Illuccix®
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 17 June 2021. Telix announces participation in a late-cycle meeting with the U.S....
Telix Pharmaceuticals and Applied Radiology launch TelixU Medical Education Platform Focused on Radiopharmaceutical Research
MELBOURNE, Australia and INDIANAPOLIS 14 June, 2021 – Telix announces the launch of a new educational platform focused on radiopharmaceutical...
Telix launches “Gallium Wave” Awareness Website
Melbourne (Australia) and Indianapolis (U.S.A.) – 11 June 2021. Telix announces the launch of a new website “Gallium Wave”, as...
Scott Law joins Telix as SVP Global Manufacturing Operations
11 June 2021 – Corporate Spotlight | Scott Law joins Telix as Senior Vice President Global Manufacturing Operations
Telix and ATS Awarded $1.56M ‘Eurostars’ Grant for Alpha Therapy
Liège (Belgium) and Gothenburg (Sweden) – 7 June 2021. Advanced Nuclear Medicine Ingredients S.A, a wholly owned European subsidiary of...